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Abstract – We report DNA immunisation experiments in cattle using plasmid constructs that en-
coded glycoprotein E2 from bovine viral diarrhoea virus (BVDV)-1 (E2.1) and BVDV-2 (E2.2). The
coding sequences were optimised for eﬃcient expression in mammalian cells. A modified leader
peptide sequence from protein gD of BoHV1 was inserted upstream of the E2 coding sequences
for eﬃcient membrane export of the proteins. Recombinant E2 were eﬃciently expressed in COS7
cells and they presented the native viral epitopes as judged by diﬀerential recognition by antisera
from cattle infected with BVDV-1 or BVDV-2. Inoculation of pooled plasmid DNA in young cattle
elicited antibodies capable of neutralising viral strains representing the major circulating BVDV
genotypes.
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1. INTRODUCTION
Bovine viral diarrhoea virus (BVDV)
is a positive strand enveloped RNA virus.
The genome comprises a single large open
reading frame flanked by untranslated re-
gions at the 5’ and 3’ ends. It is translated
into a large unique polyprotein of ∼ 4000
amino-acids. In infected cells, it is cleaved
into structural and non-structural proteins
by cellular as well as virus-encoded pro-
teases. Structural proteins are the nucleo-
capsid protein C, surface glycoproteins E0
or Erns, El and E2 [56].
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BVDV infection is widespread in cattle
worldwide and it causes important eco-
nomic losses [28]. In adult animals, infec-
tion is usually mild or subclinical although
outbreaks of haemorrhagic disease associ-
ated to BVDV have been observed [50].
Transplacental transmission during the first
three months of pregnancy causes abor-
tion or the birth of immunotolerant per-
sistently infected (PI) calves. PI animals
may look healthy but do not mount a spe-
cific immune response and shed enormous
amounts of virus. They generally succumb
from mucosal disease caused by superin-
fection by antigenically similar cytopathic
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strains. PI animals are also the main vi-
ral reservoir and source of contamination
within and between herds [1]. BVDV iso-
lates are classified within BVDV-1 and
BVDV-2 after serological cross-reactivity
and sequence relatedness. They have the
taxonomic status of viral species within
the pestivirus genus along with BDV and
CSFV [56]. Strains from both species are
circulating worldwide but with diﬀerent
distributions [53, 57]. They induce similar
diseases except that hypervirulent strains
are only found within BVDV-2 [50].
Numerous inactivated or attenuated vac-
cines are available worldwide. Most induce
horizontal protection and some claim to in-
duce vertical protection as well [32]. In
this context, DNA vaccination seems to
be a promising approach. Indeed, in the
early nineteen-nineties researchers first ob-
served that plasmid constructs expressing
an antigenic protein elicited an immune
response after mere intramuscular or in-
tradermal injection. Plasmid constructs are
easier to develop, produce and store than
conventional or subunit vaccines. Further-
more, DNA often favours the elicitation
of a type 1 cellular response that is im-
munologically favourable to the resolution
of viral infections [43]. Finally, the versa-
tility of the technology makes it possible
to design multivalent vaccines from vari-
ants of a given pathogen or from diﬀerent
pathogens as well as to devise strategies to
diﬀerentiate infected from vaccinated an-
imals. On the contrary, subunit vaccines
are more complex to develop since they
depend on eﬃcient expression systems,
protein purification and stabilised storage.
They do, however, alleviate public con-
cerns about genetically modified organ-
isms. In any case, the prerequisites for
successful vaccine design, are the choice of
the appropriate target antigen or antigens
and high expression levels of the recombi-
nant protein or proteins.
In cattle, resolution of BVDV infec-
tion is associated with neutralising anti-
bodies [30] and with a cellular response
due to CD4+ T-lymphocytes [29]. CD4+ T
cells from recovering calves are induced to
proliferate by structural proteins Erns, E2,
C and by non structural proteins NS2-3 and
Npro [13, 14].
The major surface glycoprotein E2 is
the main target of neutralising antibod-
ies [6]. Neutralising antibodies and a cellu-
lar response are produced in animals vac-
cinated with various recombinant viruses
expressing E2 [3, 17, 21], with DNA plas-
mid constructs expressing E2 [26, 42, 45]
or with E2 subunit vaccines [7, 11, 12, 39,
58]. Purified recombinant E2 from BVDV-
1a strain Singer lead to partial protection
against acute infection by the homologous
strain [7]. Another E2 subunit vaccine was
shown to induce partial fetal protection
in a sheep model of BVDV transplacental
transmission [11, 12].
This makes E2 a prime candidate anti-
gen for subunit or DNA vaccination. How-
ever, the protein sequence is variable and
cross-neutralising activity as well as cross-
reactive cellular response are often poor or
absent between viral strains from BVDV-1
and BVDV-2 [11, 26]. Also, a subunit E2
vaccine from one genotype does not pro-
tect from challenge with a strain from the
other genotype [7, 11].
In order to develop a DNA vaccine
against the wider spectrum of circulating
BVDV strains, we constructed recombi-
nant plasmids expressing the E2 proteins
from field strains of the two main BVDV
genotypes i.e. BVDV-1b and BVDV-2. Be-
sides, BVDV-1b is the most frequent sub-
type in Belgium [15, 41], in continental
Europe and probably also worldwide [53,
57]. The coding sequences were optimised
for expression in mammalian cells and
inserted under the control of the strong
CMV promoter in plasmid pCDNA3. Both
E2 proteins were eﬃciently expressed
in vitro and presented native epitopes.
BVDV-free calves were then immunised
with plasmid DNA via the intramuscular
DNA immunisation against BVDV-1 and BVDV-2 821
(IM), intradermal (ID) and intranasal (IN)
routes. They developed neutralising anti-
bodies against viral strain representatives
of BVDV-1 and BVDV-2.
2. MATERIALS AND METHODS
2.1. Virus and cells
The BVDV-1b field strain CP1945 and
the BVDV-2 field strain WVD829 had
been previously isolated from leucocytes
of PI animals at VAR and typified [15, 41].
They did not cause any discernible symp-
toms in BVDV-free bulls (unpublished ob-
servations). NADL and Osloss strains as
well as strain 890 were used in neutral-
isation experiments as representatives for
BVDV genotypes Ia, Ib and II, respec-
tively. Recent field isolates Culi4 (BVDV-
1d), L256 (BVDV-1e), WVD829 (BVDV-
2) and BSE 921 (BVDV-2) were included
too [15,41]. All strains but NADL are non-
cytopathogenic to cell cultures.
Virus titration, isolation and seroneu-
tralisation studies were performed on the
Madin Darby Bovine Kidney (MDBK)
cell line, cultured with minimum essential
medium, supplemented with 10% irradi-
ated foetal calf serum, 1% non-essential
Amino Acids, 100 ui/mL Penicillin-
Streptomycin, 50 µg/mL gentamicin and
incubated at 37 ◦C under 5% CO2. Cul-
ture media and supplements were all from
Gibco BRL Life Technologies (Gaithers-
burg, MD, USA).
2.2. Molecular biology techniques
Total RNA was extracted from BVDV-
infected MDBK cells using Trizol (Life
Technologies). The RNA was reverse-
transcribed with the Superscript II system
(Life Technologies) using random hexam-
ers as primers (Roche Molecular Biochem-
icals, Indianapolis, IN, USA). All PCR
experiments were performed using the Ex-
pand High-Fidelity PCR system (Roche
Molecular Biochemicals) in 100 µL final
volume with 1.5 mM MgCl2and thermal
cycler TC1 (Perkin Elmer Applied Biosys-
tems, Lincoln, CA, USA). PCR products
were routinely inserted into pCR3.1 by the
T/A cloning method (Invitrogen, Carlsbad,
CA, USA). Primers are listed in Table I.
Constructs were subcloned into plasmid
pCDNA3 (Invitrogen) using restriction en-
zymes and the rapid DNA ligation kit from
Roche Molecular Biochemicals.
Inserts were fully sequenced on both
strands by the dye terminator method and
the reaction products were run onto an ABI
PRISM model 310 genetic analyser (PE
Applied Biosystems).
All commercial products were used ac-
cording to the manufacturers’ instructions.
2.3. Computer-assisted analysis
of sequences
Algorithms for the management of se-
quencing projects, translation, backtransla-
tion, determination of restriction sites and
calculation of codon usage were from the
Wisconsin Package Version 10.1 (Genetics
Computer Group, GCG, Madison, Wiscon-
sin, USA).
The presence of the instability mo-
tif ATTTA was determined by visual ex-
amination of the nucleotide sequences.
This motif has been shown to confer
rapid degradation to mammalian messen-
ger RNA [5]. Putative polyadenylation
signals were searched online with the
POLYAH1 programme. RNA splice sites
were searched using the Netgene 2 pro-
gramme [10]. Probable cellular targeting
and the eukaryotic leader peptide cleav-
age site were determined with the Tar-
get P and Signal P programmes, respec-
tively [44]. Transmembrane helixes were
searched with the TMHMM version 2.0













Table I. Oligonucleotide primers for the cloning of E2 coding sequences. Start and stop codons are printed in bold. The stop codon TAA is generated
in GP53R1B when the Taq polymerase adds a non-template A at the 3’ end of amplicon E2.1. The parts of primers that actually anneal to the viral
cDNA are underlined. Restriction sites in primers are italicized.
Primer Sequence (5’ to 3’) Anneals PCR product Substrate
to position (size in bp)
GP53F1 (fwd) AAGCTTTAAGGATGATACTCATAACAGGAGC 2431-2452a E2.1 (1162) cDNA from CP1945-
GP53R1B (rev) ATCCCGAGGTCATTTGTTCTGATA 3562-3584a infected MDBK cells
GP53F2 (fwd) AAGCTTCCATAATGCTAATAACAGGGGCAC 2438-2456b E2.2 (1139) cDNA from WVD829-
GP53R2 (rev) CTAACCCATAGCCATCTGCTCAG 3558-3577b infected MDBK cells
LP1 (fwd) AAAAAGCTTGCCACCATGGAAGGGCCGACATTGGCCGT NA leader peptide (75) plasmid pCI-gD
LP2 (rev) CTGGGCCATGGTGGCCACGGCGAGCAGCGCGCCCA NA
a On the genome sequence of strain Osloss [16].
b On the genome sequence of strain 890 [49]. NA, not applicable.
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were used online at the Centre for Biologi-
cal Analysis of the Technical University of
Denmark2.
2.4. Cloning and expression of BVDV-
1 and BVDV-2 major surface
glycoprotein E2
The E2 coding sequences from BVDV-
1b strain CP1945 and BVDV-2 strain
WVD829 were amplified by PCR. Primers
(Tab. I) were chosen so as to amplify a
portion of the viral genome that encodes
the last 7–9 residues of the C-terminal hy-
drophobic region of glycoprotein E1, the
E1-E2 cleavage site and the complete gly-
coprotein E2 up to its cleavage site from
protein P7. Limits between the putative
structural proteins within the polyprotein
were determined after Becher et al. [4] and
Rümenapf et al. [51]. 5’ primers were de-
signed from previous partial sequences of
the E1-E2 coding region [15]. 3’ primers
were designed from multiple alignments
of published BVDV sequences. For both
primer pairs, cycling conditions were the
following: 94 ◦C for 2 min then 25 cycles
of 94 ◦C for 30 s, 51 ◦C for 60 s, 72 ◦C for
2 min with 20 s extension starting at cy-
cle 10, and a final incubation of 72 ◦C for
7 min.
Next, expression-optimised coding se-
quences were designed. RNA splice sites,
internal polyadenylation motifs and insta-
bility motifs were removed. Since codon
usage bias is identical in the mouse, hu-
man and bovine (not shown), the codon
frequency was also changed after highly
expressed human genes [22] while keep-
ing the native peptide sequence. Briefly,
least used codons were changed to most
used codons so that the overall codon us-
age profile became similar to the one of
highly expressed human genes. The cod-
ing sequence ended with two stop codons
in order to avoid production of “run-oﬀ”
proteins. The actual synthetic genes were
2 http://www.cbs.dtu.dk/services/
constructed by GENEART GmbH (Re-
gensburg, Germany).
The protein encoded by the synthetic
genes started four residues upstream from
the E1-E2 cleavage site so that signal
cleavage would reproduce the predicted
original N-terminus of E2: YPDCK for
CP1945 and FPECK for WVD829. The
E2 synthetic genes were subcloned into
pCDNA3 after Hind3 and XhoI enzymatic
restriction, thus creating constructs pCMV-
synE2.1 and pCMV-synE2.2 respectively.
The coding sequence for the leader pep-
tide of surface protein gD from BoHV-1
was amplified with primers LP1 and LP2
(Tab. I). The forward primer LP1 was mod-
ified to include an ATG codon in Kozak’s
consensus for eﬃcient initiation of transla-
tion [33]. Cycling conditions were 94 ◦C
for 2 min, then 25 cycles of 94 ◦C for
30 s, 60 ◦C for 30 s and 72 ◦C for 30 s.
The PCR product was digested with Hind
3 and Sfi1 and ligated into pCMV-synE2.1
and pCMV-synE2.2 at the corresponding
restriction sites in the frame at the 5’ end
of the E2 coding sequences thus creat-
ing pLP-synE2.1 and pLP-synE2.2 respec-
tively.
2.5. Transfection experiments
Plasmid DNA was routinely purified
from DH5α or TOP10F’ bacteria cells by
the quantum prep method (Biorad, Her-
cules, CA, USA). Sub-confluent COS cells
in 24-well plates were transfected in du-
plicate with 300 to 600 ng DNA per well
using lipofectamine (Invitrogen). The cells
were washed and fixed at 24 h, 48 h
and 72 h post transfection to be tested
for recognition of viral proteins by bovine
anti-BVD sera using the immunoperoxy-
dase monolayer assay (IPMA) [36].
Anti-BVDV sera had been previously
collected from BVDV-free calves experi-
mentally infected with selected genotyped
BVDV strains [23, 24, 41]. They were rou-
tinely diluted 1/300 in PBS-0.1% NaN3.
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We also investigated the cellular lo-
calisation of the two E2 glycoproteins.
In this research group, the results of in-
vestigations on the localisation of cloned
BoHV-1 structural proteins using a modi-
fied IPMA were consistent with confocal
microscopy [54]. Therefore, we consid-
ered the former as a reliable approach.
COS cells in 24-well plates were tran-
siently transfected with plasmid constructs
expressing gD (pCI-gD) [54], protein N
(pNsyn) [8] and our new constructs pCMV-
LPsynE2.1 and pCMVL-PsynE2.2. Af-
ter 48 h, half the culture plates were
first dried then frozen at –20 ◦C and fi-
nally fixed with 4% formaldehyde, leading
to permeabilisation of membranes (per-
meabilised condition). In the other half,
we avoided permeabilisation by staining
life cells and by avoiding detergent in
all buﬀers (non-permeabilised condition).
Cell cultures were then incubated with
the respective specific anti-gD, anti-N and
anti-E2 bovine antisera. Non-transfected
controls were incubated with the anti-E2
antiserum only.
2.6. Large-scale production of plasmid
DNA for DNA immunisation
Large amounts of plasmid DNA were
produced by alkaline lysis of overnight
DH5α bacterial cultures followed by aﬃn-
ity chromatography on anion-exchange
resin (Plasmid Giga kit, Qiagen, Hilden,
Germany). Columns were regenerated and
re-used up to four times as described
by Gregory et al. [20]. Typically, lysates
from two 2.5 L cultures were each pas-
saged twice through a single column. The
DNA was eluted in sterile bi-distilled wa-
ter. Each individual batch or passage was
quantitated by spectrometry and gel elec-
trophoresis and tested for expression in
COS cells. First passage batches typically
produced 8 to 12 mg DNA whereas second
passages produced ∼50% of first passage
yields. No consistent diﬀerences in purity
or in expression levels were observed be-
tween batches. Therefore, batches for a
given construct were pooled before inoc-
ulation.
2.7. DNA immunisation in cattle
All manipulations were conducted in
isolation facilities. Danish crossbred male
calves, negatives for BVDV virus and
antibodies were purchased from Husdyr-
formidling Syd (Rødekro, Denmark). The
animals were maintained and handled ac-
cording to local and national ethical guide-
lines.
DNA for the IN route was made
into a cationic liposome DNA complex
by timely mixing up the DNA with
protamine (Sigma) and diC(14)-amidine
(vectamidineTM, Biotech Tools, Brussels,
Belgium) following a 1:0.6:4 molecu-
lar ratio after Elouahabi et al. [18]. In-
tranasal instillation was performed by
dropping the DNA-protamine-vectamidine
complexes in 7.5 mL saline into both nos-
trils. For the IM inoculation route, 2.5 to
2.75 mL of DNA solution was injected into
a single site located at the base of the neck.
The ID route consisted in injecting 1.1 to
1.3 mL into 4 to 7 points into the shaven
and disinfected (isobetadine) skin of the
neck.
Three bulls aged ∼8.5 months each re-
ceived 3 injections of 1 mg plasmid DNA
consisting in 500 µg pLP-synE2.1 and
500 µg pLP-synE2.2 in sterile endotoxin-
free PBS (Sigma, St. Louis, MO, USA).
In the first injection, the DNA dose
was fractionated into three inoculums:
(1) intramuscular: 333 µg, (2) intradermal:
333 µg, (3) intranasal: 333 µg. At day
21, the animals were given a first booster
of the same material by the IM (500 µg)
and ID (500 µg) routes only. A second,
identical booster was given at day 69.
A fourth bull was kept not inoculated to
monitor environmental contamination by
pestiviruses. Blood samples were taken at
the days of inoculation, two weeks after the
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Table II. Features of the E2 coding sequences.
Coding sequence Accession Size Splice sites Other % Expression
numbe (bp) Donor Acceptor motifs GC in COS cells
Native type 1 E2 AJ715391 1152 5 7 ins. (2X) 46 No
Native type 2 E2 AJ715392 1143 7 5 polyAd., ins. 44 No
Synthetic type 1 E2 AJ715393 1134 0 0 None 59 Strong
Synthetic type 2 E2 AJ715394 1128 0 0 None 57 Strong
polyAd., Polyadenylation signal; ins., instability motif ATTTA.
first and second injections then every week
for 1.5 months.
2.8. Assessment of the humoral
response
Sera from all calves were tested for neu-
tralising antibodies against viral strain rep-
resentatives of the three main BVDV geno-
types: Osloss (nc) for BVDV-1b; NADL
(cp) for BVDV-1a and 890 (nc) for BVDV-
2. Additional experiments were conducted
on strains Culi4 (1d), L256 (1e), WVD829
(2) and BSE921 (2) recently isolated from
field samples in Belgium [15, 41]. Tests
were conducted in microtitre plates con-
taining confluent monolayers of MDBK
cells. All sera were tested in duplicate in
two-fold dilution, starting at dilution 1:2,
against 64 to 128 TCID50 of virus. Un-
neutralised virus was detected by indirect
immunofluorescence staining using a pool
of monoclonal antibodies as primary anti-
bodies [9].
3. RESULTS
3.1. Cloning and expression of BVDV
E2 proteins
The coding sequences for E2 from field
isolates CP1945 (BVDV-1b) and WVD829
(BVDV-2) were isolated by RT/PCR and
inserted into the pCR3.1 mammalian ex-
pression vector. The new sequences were
submitted to the EMBL database and as-
signed accession numbers AJ715391 and
AJ715392 respectively. No viral proteins
were detected by IPMA using bovine an-
tisera against BVDV after transfection of
COS cells (not shown).
Analysis of the sequences revealed the
presence of (i) donor and acceptor RNA
splice sites, (ii) an internal polyadenyla-
tion motif, (iii) the mRNA instability motif
ATTTA (Tab. II). The codon usage was
also found to be very diﬀerent from the
average codon usage in mammalian cells
(i.e. bovine, murine or human). Therefore,
the nucleotide sequences were optimised
for expression and synthetic genes were
constructed accordingly. They were as-
signed accession numbers AJ715393 and
AJ715394 respectively. As compared to
their cognate native sequences, the opti-
mised ones were 84% identical at the nu-
cleotide level and 100% identical at the
amino-acid level. The G or C contents in-
creased from ∼45% to ∼58% (Tab. II).
The synthetic genes were then inserted
into plasmid pCDNA3.1 to create pCMV-
synE2.1 and pCMV-synE2.2. Only the lat-
ter gave a weak signal on COS transfected
cells after IPMA using a hyperimmune
bovine antiserum (Tab. III and Fig. 1).
Secondly, a modified leader peptide se-
quence from protein gD of BHV-1 was
amplified by PCR. Sequence analysis with
Target P indicated that the leader pep-
tide belonged to the highest reliability
class (RC = 1) for a secretory path-
way. The nucleotide sequence has 67% G
or C and an average mammalian codon
usage; it lacked splice sites or instability
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Figure 1. Transient expression of BVDV E2 glycoproteins in Cos7 cells. Cos7 cells were
transfected with the following plasmid DNA and stained with polyspecific anti-BVDV calf
antiserum DSV229/2 by the IPMA method. (1) pCMV- synE2.1; (2) pCMV_synE2.2.; (3) pCMV-
LP_synE2.1; (4) pCMV-LP_synE2.2.
motifs. The amplicon (AJ715399) was di-
gested with HindIII and Sfi1 and sub-
cloned inframe at the 5’ end of the op-
timised E2 sequences thus creating pLP-
synE2.1 and pLP-synE2.2. The chimerical
sequences were assigned accession num-
bers AJ715395 and AJ715396 respectively.
The new constructs directed high produc-
tion of the E2 protein as detected by bovine
antisera on transfected COS cells (Fig. 1).
Trans-membrane anchor hydrophobic
helices were detected with the TMHMM
programme (not shown) and transfected
COS cells were tested in conditions
where membranes are preserved. Our
recombinant E2 were thus considered
membrane proteins.
Next, transfected COS cells were tested
with a series of anti-BVDV calf antisera
(Tab. III). Recognition paralleled the dis-
tinction between BVDV-1 and BVDV-
2. Sera from calves infected with vari-
ous BVDV-1 strains recognised COS cells
transfected with pLP-synE2.1 but not COS
cells transfected with pLP-synE2.2. Con-
versely anti-BVDV-2 sera recognised COS
cells transfected with pLP-synE2.2 but not
with pLP-synE2.1. A very strong cross-
recognition was observed with antisera
from calves that had been vaccinated
with a BVDV-1 inactivated vaccine and
challenged one month later with BVDV-2
thrombocytopenic strain 890.
Finally, we investigated the cellular lo-
calisation of E2.1 and E2.2. Subconflu-
ent COS7 cells were transfected in par-
allel with plasmid constructs expressing
(i) glycoprotein gD from BoHV-1 (pCI-
gD), (ii) protein N of BRSV (pNsyn), and
(iii) E2 from BVDV-1 (pCMV-synE2.1)
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Table III. Specific recognition of BVDV-1 and BVDV-2 E2 by bovine antisera. Reactivity to type I
and type E2 was detected on COS cells transfected with sequence-optimised constructs using anti-
BVDV antisera and anti-bovine secondary antibody conjugated to peroxydase. BVDV strains and
bovine antisera indicated here have been characterised before [15, 24, 41]. Serum DSV 229/2 comes
from an animal vaccinated with the MucobovinTM vaccine then challenged with strain 890/256 [24].
Mouse monoclonal antibody 8H5-111 was developed against strain New-York-I.
Antiserum BVDV strain (genotype) LP_E2.1 LP_E2.2
CSV 229/1 NADL (1a) P. N.
CSV 229/2 BVR 1199 (1a) P. N.
2269 Marloie (1b) P. N.
8H5-111 New-York (1b) P. N.
ASV 545/6 CULI 4 (1d) P. N.
ASV 684/1 L256 (1f) P. N.
ASV 620 L256 (1f) PP. p.
DSV 229/2 Averonite (BDV), New-York (1b)+890 (2) PP. PP.
BSV 570 890 (2) N. P.
2270 WVD829 (2) N. P.
N. Negative; p. weak positive; P. positive; PP. strong positive.
and BVDV-2 (pCMV-synE2.2). After 48 h
incubation, cells in permeabilised and non-
permeabilised conditions were incubated
with the respective specific antisera ac-
cording to the IPMA method. The results
are shown in Figure 2. As expected, COS
cells transfected with plasmid pCI-gD ap-
peared stained in non-permeabilised and
permeabilised conditions whereas cells
transfected with pCMV-N were found
stained in the permeabilised condition
only. A large number of cells trans-
fected with plasmids expressing E2.1 and
E2.2 were stained in the permeabilised
condition but, surprisingly, a proportion
of them were also positive in the non-
permeabilised condition. We concluded
that E2 is directed to the cell surface in
some of the transfected cells.
Constructs pLP-synE2.1 and pLP-
synE2.2 were thus selected for DNA
vaccination experiments in cattle.
3.2. DNA vaccination elicited a cross-
neutralising humoral response
Pooled pLP-synE2.1 and pLP-synE2.2
plasmid DNA was given by the IM, IN
and ID routes simultaneously. Neutralis-
ing antibodies were monitored on BVDV-
1a strain NADL. One animal showed a
transient low-level response (titre = 2) at
week 2 after the second DNA inoculation.
All three vaccinated animals seroconverted
after the third injection, indicating that im-
munity towards heterologous strains (i.e.
not the ones from which the E2 sequences
had been cloned) had been obtained. The
sera also neutralised Osloss (BVDV-1b)
and 890 (BVDV-2) strains, indicating that
the response concerned the wider range
of BVDV. We noticed a lower neutralisa-
tion titre towards 890 and NADL as com-
pared to Osloss. The one control animal
remained seronegative throughout the ex-
periment, thus excluding concomitant pes-
tivirus contamination (Tab. IV).
4. DISCUSSION
We report DNA immunisation ex-
periments in cattle using plasmid con-
structs that encode full-length versions of
sequence-optimised glycoprotein E2 from
BVDV-1 (E2.1) and BVDV-2 (E2.2).
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Figure 2. Localisation of recombinant proteins in transfected COS7 cells. COS cells in 24-well
plates were transfected with plasmid constructs expressing E2 from BVDV-1b (pCMV-LPsynE2.1),
E2 from BVDV-2 (pCMV-LPsynE2.2), surface protein gD from BoHV1 (pCI_gD) and the nucleo-
capsid N protein from BRSV (pNsyn). Non-transfected cells were included as controls. After 48 h
at 37 ◦C, half the culture plates were incubated with the respective specific bovine antisera the per-
meabilised (left column) or non-permeabilised condition (right column) using the IPMA method.
Non-transfected cells were incubated with the anti-E2 antiserum only.
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Table IV. Neutralising titres against representative BVDV strains after DNA immunisation. Three
BVDV-negative crossbred bulls were inoculated with pooled pLP-synE2.1 and pLP-synE2.2 DNA
by the combined IM, ID and IN routes and boosted twice by the combined IM and ID routes.
One bull was kept non-vaccinated as an environmental control. Sera were analysed for neutralising
antibodies two weeks after the second boost.
Animal N◦ NADL Osloss Culi4 L256 WVD829) BSE921 890
(1a) (1b) (1d) (1e) (2) (2) (2)
1 (vaccinated) 16 256 64 128 32 16 64
2 (vaccinated) 16 512 128 64 8 8 16
3 (vaccinated) 32 512 128 64 16 16 32
4 (unvaccinated) < 2 < 2 < 2 < 2 < 2 < 2 < 2
At first, no protein expression was de-
tected from plasmid constructs contain-
ing the native E2 sequences downstream
of the strong CMV promoter in plasmid
pCDNA3 (data not shown). The sequences
were shown to contain internal splice sites,
and a polyadenylation motif as well as an
“instability” (ATTTA) motif (Tab. II). The
codon usage was also found to be very
divergent from the codon usage of mam-
malian cells. We then constructed synthetic
E2 genes removing unwanted motifs and
changing the codon usage after a table
of highly expressed human genes. A low
level of the E2 protein in COS cells was
then detected by bovine antisera but only
from the E2.2 construct. A modified ver-
sion of the leader peptide from BoHV1
protein gD was then inserted inframe to
the 5’ end of both E2.1 and E2.2. The
new constructs were strongly recognised
by sera from calves that had recovered
from BVDV infection.
High levels of expression were ob-
tained with optimised E2 coding sequences
downstream of a modified gD leader pep-
tide. Removing internal splice sites as well
as polyadenylation and A-T rich stretches
(“instability” motifs) probably resulted in
an increased stability and thus increased
steady-state amounts of the specific mes-
sengers. Changing codon frequencies after
a table of highly expressed human genes
probably increased the levels of transla-
tion of individual mRNA molecules thanks
to a better availability of the tRNA pool.
Finally, eﬃcient export to the membrane
meant that relevant neutralising epitopes
were (better) exposed. In the field of
DNA vaccination, this approach is often
used successfully for various types of anti-
gens [2]. The various types of modifi-
cations applied here have recently been
shown to act synergistically in improving
the success of an HIV gp120 DNA vac-
cine [59].
Because E2 is initially part of the
BVDV polyprotein, which is then pro-
cessed into individual structural proteins
during the BVDV infection cycle [56], it
does not possess its own leader peptide,
which therefore must be added experimen-
tally. Other authors had previously used the
signal peptide from a mouse IgG κ light
chain [45], from gD of BoHVI [3, 42],
tPA [42] or from BVDV Erns [52]. In the
early E2 construct of Harpin et al. [26],
the 3’ end of the E1 coding sequence was
retained at the 5’ end of the E2 coding
sequence. In the expressed recombinant
E2, the 16-residues C-terminal hydropho-
bic stretch of protein E1 probably acts as a
signal peptide. We chose gD because se-
quence analysis as well as experimental
data of our research team [55] indicated
that it is highly expressed and eﬃciently
directs membrane export of the protein. Its
coding sequence was modified to permit
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straightforward cloning at the 5’ end of E2
while keeping the native amino-terminal
end of the E2 protein after cleavage.
The observation that only cells express-
ing E2 from constructs containing the
leader peptide are strongly recognised by
bovine antisera suggests that proper pro-
cessing and/or membrane export is essen-
tial (Fig. 1). Diﬀerential recognition of
E2.1 and E2.2 recombinant protein by an-
tisera from calves infected with BVDV-1
or BVDV-2 strains (Tab. III) further in-
dicated that native antigenic determinants
were conserved.
Finally, the cellular localisation of E2
was investigated by IPMA on transfected
COS cells in permeabilised and non-
permeabilised conditions (Fig. 2). We con-
sidered IPMA as a reliable approach be-
cause Toussaint et al. [55] in this research
group, showed that their results are con-
sistent with confocal microscopy. We thus
compared the localisation of E2 with bona
fide surface protein gD of BoHV-1 and cy-
toplasmic protein N of BRSV. As expected
gD, but not N, was observed at the cell
surface. A proportion of COS cells trans-
fected with pCMV-LPsynE2.1 and pCMV-
LPsynE2 expressed E2 at the cell surface.
This was surprising because glycoprotein
E2 is normally not transported to the cell
surface but retained in the endoplasmic
reticulum [34]. This is due to the presence
of an arginine residue within the membrane
anchor of E2 [34]. The arginine residue is
also observed in the amino-acid sequence
of membrane anchors of our recombinant
E2. However, surface localisation of E2
has also been observed in cells infected
with recombinant baculovirus [39] or re-
combinant VSV [21] that express E2. As
suggested by Köhl et al. [34, 35] it is con-
ceivable that, in some transfected cells,
the cell retention machinery becomes sat-
urated by overexpressed E2 glycoproteins
which are then transported to the cell sur-
face.
The two E2 constructs (pCMV-
LPsynE2.1 and pCMV-LPsynE2.2) were
injected into 3 bulls by the combined
IM, ID and IN routes. All animals se-
roconverted after three injections of
1 mg pooled DNA. Seroneutralisation
experiments were performed on a total of
4 strains from various BVDV-1 subtypes
and 3 BVDV-2 strains. They were labora-
tory strains (NADL, Osloss), recent field
isolates from PI animals (Culi4, L256,
WVD829, BSE921) and a virulent strain
(890), a cytopathogenic strain (NADL)
and several non-cytopathogenic ones. All
were neutralised by sera from bulls after
DNA immunisation (Tab. IV).
We concluded that our E2 constructs
were immunogenic to the bovine species
and elicited a cross-reactive humoral re-
sponse to the wider range of BVDV strains.
i.e. not only the ones from which the cod-
ing sequences had been cloned.
In recent years, several research
teams have reported DNA immunisa-
tion to BVDV structural proteins in the
mouse [26, 42, 45, 46] and cattle [27,
47, 42]. All experiments involved E2
constructs from a single BVDV-1a viral
strain. In most reports, cross-neutralisation
with strains from other genotypes was
not tested. Harpin et al. [26, 27] showed
that 3/4 vaccinated mice cross-neutralised
BVDV-1b strain New-York as well as
BVDV-1a NADL but not BVDV-2 strain
125, indicating that cross-neutralisation
is restricted to the genotype from which
the coding sequence had been cloned.
Another report by Nobiron et al. [46]
showed that the response to heterologous
strain NADL was much lower in terms
of titres and numbers of responding mice
than to homologous strain Ky1203nc
though both belong to the same genotype
Ia. In cattle, the antibodies neutralised
only homologous strain Ky1203nc but not
NADL [47]. This diﬀerence could be due
to diﬀerences in recombinant E2. Indeed,
whereas Harpin’s construct encodes a
DNA immunisation against BVDV-1 and BVDV-2 831
full-length E2 including its predicted
native cleavage site and hence native
N-terminus, Nobiron’s is deleted at the
C-terminus and uses an immunoglobulin
signal peptide with its own cleavage site
thus creating a truncated E2 protein with a
chimeric N-terminus (the first 17 residues
of the mature protein are from the multiple
cloning site of vector pSecTag). Although
titres were higher with the truncated E2
construct, cross-neutralisation of strains
within genotype Ia was absent or poor even
when genetic adjuvant IL-2 and GM-CSF
were co-inoculated [45, 46]. Accordingly,
cross-neutralisation of BVDV strains from
the same viral species depended on the in-
tegral E2 protein which should include its
native N-terminus. Besides, neutralisation
of viral strains across the genotype divide
is not observed when using E2 constructs
from BVDV-1 solely.
When testing BVDV-1 strains, we ob-
served that neutralising titres were lower
towards NADL and higher to Osloss. They
did not diﬀer amongst BVDV-2 strains.
The amino-acid sequences of E2 from
NADL and Osloss are 71% and 84% iden-
tical, respectively, to injected E2.1. Be-
sides, the E2 of BVDV-2 strain WVD829
is 100% identical to injected E2.2 whereas
E2 from the other BVDV-2 strains tested
are only 91% identical to injected E2.2.
This suggested that genetic distance alone
does not explain the observed diﬀerences
in titres. The cytopathogenic (CP) or non-
cytopathogenic (NCP) biotype or other
properties of testing strains might play a
role. Finally, when comparing only NCP
strains from the two species, titres were
lower towards BVDV-2 strains than to-
wards BVDV-1. This suggested that dif-
ferences in immunogenicity or expression
levels of the two E2 proteins might also
play a role.
Recombination between the viral
genome and cellular or viral RNA is
known to occur in pestiviruses including
BVDV. It may lead to the appearance
of the cytopathogenic biotype in non-
cytopathogenic strains [38] and it is
suspected to generate variability [31].
Therefore the risk of in vivo recombina-
tion between an injected DNA vaccine
(plasmids) and a field BVDV isolate is
worth considering. First, cell lines con-
tinuously expressing structural proteins
including E2 cannot be superinfected
with BVDV [25, 48] and E2 was recently
shown to be responsible for blocking
the entry of superinfecting BVDV [40].
Therefore bovine cells expressing E2
after DNA vaccination probably have a
very low chance of being infected by the
virus. Admittedly, DNA vaccination in
PI calves might lead to viral genomic
RNA and RNA from the injected plasmid
being present in the same cells but, since
PI calves are normally screened for and
culled, this would be very infrequent.
Secondly, in order to generate viable
viruses, non-homologous recombination
between messengers from the injected
plasmid constructs and the viral genome
will have to be inframe and not lead to
disruption of the coding sequences for
essential viral proteins. The changed G and
C content of the E2 coding sequences in
the injected constructs will greatly reduce
the chances of homologous recombination.
Homologous recombination is a minor
mechanism for BVDV but it has been
documented [19, 31]. Third, viable virus
expressing E2 from the DNA vaccine will
probably be neutralised by anti-E2 anti-
bodies elicited by the DNA immunisation
itself. Acquisition of a CP biotype due to
insertion of E2 sequences has not been
documented so far [38]. We conclude that
the danger associated with the recombina-
tion between a DNA vaccine expressing
E2 and a field BVDV isolate is probably
very small.
In conclusion, we have shown here
that sequence-optimised E2 glycoproteins
were eﬃciently expressed in vitro and
presented native antigenic determinants.
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Cross-neutralising antibodies were elicited
in bulls when inoculated with pooled plas-
mid DNA. This is a promising first step
to making a cross-protective DNA vac-
cine against BVDV. It remains to be seen
whether our E2 can lead to eﬀective pro-
tection against viral challenge. The most
eﬃcient inoculation route should be deter-
mined too. Because of demonstrated im-
munogenicity and high levels of expression
they achieved, our constructs may also be
useful to prepare recombinant proteins to
be included in a subunit vaccine.
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